TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

ABIONYX Pharma Reveals Preclinical Results for CER-001 in Addressing Brain Fog at the 1st International Scientific Congress on Brain-kidney Interaction in Naples

Friday, November 24, 2023

ABIONYX Pharma, a forward-thinking biotech company committed to advancing therapies utilizing the world's only natural recombinant apoA-I, is set to unveil novel preclinical findings on CER-001's effectiveness in addressing brain dysfunction associated with acute kidney injury. This announcement precedes the 1st International Congress on brain-kidney interaction in Naples, Italy, scheduled for November 23-24, 2023.

Building on earlier presentations at the 2023 Annual Meeting of the American Society of Nephrology, where CER-001's impact on brain dysfunction induced by acute kidney injury was showcased, ABIONYX Pharma continues to make significant strides in the field. The absence of effective preventive or therapeutic solutions for kidney injury-related brain dysfunction, particularly in conjunction with sepsis, underscores the importance of this research.

A preclinical study sponsored by ABIONYX Pharma examined the effects of recombinant apoA-I phospholipid complexes in mitigating the inflammatory process and preventing sepsis-induced acute renal failure and associated brain dysfunction. In both CER-001 dose groups (20 mg/kg and 2x20 mg/kg), there were noteworthy reductions in Indolamine-2,3-dioxygenase enzyme activity and quinolinic acid levels in blood samples compared to the control group. Additionally, systemic and brain interleukin-6 (IL-6) levels significantly decreased after CER-001 treatment.

These findings suggest that CER-001 treatment holds promise in reducing inflammation, eliminating neuroactive compounds, and potentially enhancing renal and cognitive function in sepsis-induced acute renal failure. The results open avenues for future clinical trials in potential applications such as neuropsychiatric lupus and, notably, long Covid.

Professor Loreto Gesualdo, Head of the Unit of Nephrology, Dialysis, and Transplantation at the University of Bari Aldo Moro in Italy, and principal investigator of the RACERS study, commends the broad efficacy spectrum of CER-001. The unique properties of recombinant apoA-I lipoprotein complexes seem to address both kidney and brain disorders in sepsis patients, supporting the clinical development of CER-001 in novel indications affecting the gut-kidney-brain axis.

The upcoming oral presentation at the international congress on November 24, 2023, titled "Gut-Brain-Kidney: the stunning interplay," promises to shed further light on these groundbreaking developments.

Brain fog, characterized by a decline in mental functioning, is a set of symptoms associated with partial convalescence following sepsis-induced acute renal failure. Emerging research highlights the enduring consequences and heightened risk of chronic dysfunction and neurocognitive decline even after the resolution of acute sepsis-induced renal failure, emphasizing the intricate link between kidney damage and cerebral dysfunction.

 

Source: businesswire.com

patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO Summit